Аналитики оценили акции Bicycle Therapeutics как «удерживать» при росте интереса институциональных инвесторов

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC – Get Free Report) has earned an average rating of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $13.8571. A number of equities research analysts have issued reports on the stock. Needham & Company LLC reduced their price objective on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Wednesday, July 8th. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a research report on Wednesday, June 3rd. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Get Our Latest Stock Report on Bicycle Therapeutics Bicycle Therapeutics Stock Performance Bicycle Therapeutics (NASDAQ:BCYC – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.14). Bicycle Therapeutics had a negative net margin of 311.11% and a negative return on equity of 33.22%. The company had revenue of $0.63 million during the quarter, compared to analyst estimates of $4.22 million. On average, research analysts predict that Bicycle Therapeutics will post -2.23 earnings per share for the current fiscal year. Insiders Place Their Bets In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,905 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total value of $25,214.35. Following the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. This trade represents a 0.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 9,977 shares of company stock worth $42,702 in the last three months. 22.00% of the stock is owned by corporate insiders. Hedge Funds Weigh In On Bicycle Therapeutics Institutional investors have recently modified their holdings of the business. Clearstead Advisors LLC boosted its stake in Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares in the last quarter. GAMMA Investing LLC grew its position in Bicycle Therapeutics by 512.9% in the second quarter. GAMMA Investing LLC now owns 7,704 shares of the company’s stock valued at $33,000 after acquiring an additional 6,447 shares during the last quarter. Pinnacle Wealth Management Advisory Group LLC bought a new position in Bicycle Therapeutics in the fourth quarter valued at about $71,000. Ausdal Financial Partners Inc. acquired a new position in Bicycle Therapeutics during the second quarter worth about $70,000. Finally, Vontobel Holding Ltd. acquired a new position in Bicycle Therapeutics during the fourth quarter worth about $71,000. Institutional investors and hedge funds own 86.15% of the company’s stock. About Bicycle Therapeutics Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology. Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners. Recommended Stories Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.